| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Robert V Gunderson Jr. is Director at TBPH, with reported holdings spanning 2 companies. Robert V Gunderson Jr.'s net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
Robert V Gunderson Jr.'s largest disclosed position is in TBPH as Director, worth about $1.2M.
Robert V Gunderson Jr. has 9 Form 4 filings on record from April 2015 to May 2026, across 2 companies: Director at Andersen Group (ANDG), 2025–2026; Director at Theravance Biopharma (TBPH), 2015–2021.
The 13 reported transactions were 7 stock awards, 4 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $287K and no sales.
The largest open-market purchase was 12,633 shares of ANDG at an average $16.00 on December 18, 2025, about $202K.